The European cannabis industry continues to expand, but cultivators often face obstacles when sourcing reliable and high-quality plant genetics. Segra International, a global leader in cannabis ag-tech and genetics, has formed a strategic partnership with GreenBe Pharma, a premier medicinal cannabis producer in Portugal, to address these challenges. Through this collaboration, Segra’s sought-after tissue culture cannabis clones will be distributed locally, simplifying the supply chain for growers in Europe and reducing the need for complex imports.

By making these elite cultivars available at GreenBe Pharma’s European facility, the process becomes more efficient and cost-effective. Cultivators throughout the continent no longer have to endure prolonged waiting periods or navigate complicated import regulations. Instead, they can readily obtain the clones they need, allowing them to respond quickly to market demands and streamline production schedules. This improvement in access stands to help cultivators stay competitive in a rapidly evolving industry.

Segra International is known for its advanced tissue culture methods, which ensure that each clone meets strict standards for genetic consistency and pathogen control. These measures play a vital role in maintaining plant health and uniformity in the field. Growers often seek stable cannabinoid and terpene profiles, and Segra’s techniques help achieve precisely that. The company’s dedication to innovation sets a benchmark for quality and dependability, values that are essential in the European market.

GreenBe Pharma plays an equally important role in this partnership. The Portuguese company focuses on cultivating, processing, and commercializing cannabis plants under Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP) standards. Its facilities are designed to maintain tight environmental controls and thorough quality protocols, making them well-suited for housing Segra’s top-tier clones. This synergy ensures that European cultivators receive consistently healthy, high-performing plants.

The partnership aims to remove long-standing bottlenecks, such as regulatory barriers and extended lead times, that have historically hampered growers’ access to elite cannabis genetics. The availability of cannabis clones in Europe through this alliance can shorten production cycles, improve yields, and enable growers to keep pace with shifting consumer needs. With more reliable and timely access to quality plant material, cultivators can focus on optimizing their operations rather than dealing with the complexities of importing genetics.

Both Segra International and GreenBe Pharma expect this agreement to yield significant benefits for the broader cannabis community. Faster delivery, reduced overhead, and improved product consistency are essential elements in establishing a robust European cannabis supply chain. As demand continues to rise, driven by medicinal use, research developments, and changing regulations, this collaboration stands to positively influence the entire industry. High-quality, pathogen-tested clones can help producers maintain a competitive edge while also meeting stringent quality expectations.

For more information about GreenBe Pharma, visit their website at https://greenbepharma.com.